Search Result

Results for "

S1P

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (9) Aryl Hydrocarbon Receptor (3) Autophagy (3) Bcl-2 Family (1) Biochemical Assay Reagents (1) Ceramidase (2) Endogenous Metabolite (3) ERK (1) Fatty Acid Synthase (FASN) (2) Fluorescent Dye (1) Isotope-Labeled Compounds (3) Leukotriene Receptor (2) LPL Receptor (114) P-glycoprotein (2) PAK (6) PI3K (1) Smo (1) SphK (9) TRP Channel (1) Virus Protease (2)
By Research Areas:	Cancer (26) Cardiovascular Disease (13) Endocrinology (3) Infection (4) Inflammation/Immunology (79) Metabolic Disease (7) Neurological Disease (23)

131

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108496

Sphingosine-1-phosphate 5+ Cited Publications S1P	Endogenous Metabolite LPL Receptor	Inflammation/Immunology Endocrinology Cancer
Sphingosine-1-phosphate (S1P) is an agonist of S1P_1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca ²⁺ as an extracellular ligand for G protein-coupled receptors ^[1]. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids . Sphingosine-1-phosphate stimulates the DNA synthesis, cell proliferation and migration .

HY-101265

Icanbelimod S1P receptor agonist 1	LPL Receptor	Inflammation/Immunology
Icanbelimod (S1p receptor agonist 1) is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). Icanbelimod is extracted from patent WO2015039587A1, Compound 2.

HY-108496S

Sphingosine-1-phosphate-d7 S1P-d₇	Endogenous Metabolite LPL Receptor	Endocrinology
Sphingosine-1-phosphate-d₇ is the deuterium labeled Sphingosine-1-phosphate. Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca2+ as an extracellular ligand for G protein-coupled receptors[1]. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids[2].

HY-12835

S1P1 agonist III	LPL Receptor	Inflammation/Immunology
S1P1 Agonist III is a potent and orally active S1P1 agonist with EC50 of 18 nM; no activity on S1P3.

HY-104069

S1P1 agonist 1	LPL Receptor	Inflammation/Immunology
S1P1 Agonist 1 is a *S1P1* agonist with immunomodulatory activities.

HY-148115

S1p receptor agonist 2	LPL Receptor	Inflammation/Immunology
S1p receptor agonist 2 (compound 1) is an agonist of S1P5 receptor, exhibits selectivity over the *S1P1* and/or S1P3 receptors. S1p receptor agonist 2 can be used for endogenous SIP signaling system research, and alleviating or preventing CNS disorders research, such as neurodegenerative disorders ^[1].

HY-115566

S1PL-IN-1	LPL Receptor Smo	Inflammation/Immunology
S1PL-IN-31 (compound ) is an oral active sphingosine-1-phosphate (S1P) lyase inhibitor with the IC₅₀ of 210 nM. S1PL-IN-31 is Smoothened receptor antagonist with the IC₅₀ of 440 nM. S1PL-IN-31 can be used for study of experimental autoimmune encephalomyelitis ^[1] .

HY-143864

S1PR1 agonist 1	LPL Receptor	Inflammation/Immunology
S1PR1 agonist 1 is a potent agonist of *S1PR1. Sphingosine-1*-phosphate (S1P) is a cell membrane-derived lysophospholipid signalling molecule that exerts its physiological functions mainly by stimulating some members of the G protein-coupled receptor family. S1PR1 agonist 1 has the potential for the research of autoimmune diseases (extracted from patent WO2021175223A1, compound 22) ^[1].

HY-143865

S1PR1 agonist 2	LPL Receptor	Inflammation/Immunology
S1PR1 agonist 2 is a potent agonist of *S1PR1. Sphingosine-1*-phosphate (S1P) is a cell membrane-derived lysophospholipid signalling molecule that exerts its physiological functions mainly by stimulating some members of the G protein-coupled receptor family. S1PR1 agonist 2 has the potential for the research of autoimmune diseases (extracted from patent WO2021175225A1, compound 1) ^[1].

HY-144126

S1P1 agonist 5	LPL Receptor	Inflammation/Immunology
S1P1 agonist 5 is a selective and orally active *S1P1* agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS) ^[1].

HY-141845

S1P2 antagonist 1	LPL Receptor	Others
S1P2 antagonist 1 is an orally bioavailable *S1P2* antagonist against fibrotic diseases.

HY-148198

S1P5 receptor agonist-1	LPL Receptor	Inflammation/Immunology
S1P5 receptor agonist-1 (example 6) is a potent and selective agonist of S1P₅ receptor with an EC₅₀ value of 20 nM ^[1].

HY-156565

S1P1 agonist 6	LPL Receptor	Inflammation/Immunology
S1P1 agonist 6 (Compound I) is a *S1P1* agonist that reduces autoimmune ability by blocking the transportation of lymphocytes. S1P1 agonist 6 can be used as an immunosuppressive agent in the study of various autoimmune diseases research ^[1].

HY-156565A

S1P1 agonist 6 hemicalcium	LPL Receptor	Inflammation/Immunology
S1P1 agonist 6 hemicalcium (Compound I) is a *S1P1* agonist that reduces autoimmune ability by blocking the transportation of lymphocytes. S1P1 agonist 6 hemicalcium can be used as an immunosuppressive agent in the study of various autoimmune diseases research ^[1].

HY-117213

Ex26 S1P1-IN-Ex26	LPL Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Ex26 (S1P1-IN-Ex26) is a potent and selective sphingosine 1-phosphate receptor 1 (S1P₁) antagonist (IC₅₀=0.93 nM). Ex26 shows >3,000-fold selectivity for S1P₁ over other Sphingosine 1-phosphate receptors. Ex26 can be used in experimental autoimmune encephalomyelitis reseach ^[1].

HY-115831

SAR247799 S1P1 agonist 3	LPL Receptor	Cardiovascular Disease
SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist, with EC₅₀s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome ^[1] .

HY-W127793

EDTA-p-Bromoacetamido benzyl (S)-1-(p-Bromoacetamidobenzyl)ethylenediaminetetraacetic acid	Biochemical Assay Reagents	Others
EDTA-p-Bromoacetamido benzyl ((S)-1-(p-Bromoacetamidobenzyl)ethylenediaminetetraacetic acid) is a compound of EDTA and phenylbromoacetamide that can be coupled to antibodies ^[1].

HY-145362

S1P1 agonist 4	LPL Receptor	Others
S1P1 agonist 4 has a better profile in both potency (EC₅₀ < 0.05 mg/kg) and predicted human half-life (t1/2 ∼ 5 days).

HY-P99318

Sonepcizumab LT 1009; Anti-Human S1P Recombinant Antibody	LPL Receptor	Cancer
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) ^[1].

HY-150254

SLB1122168	LPL Receptor	Inflammation/Immunology
SLB1122168 is a potent Spns2-mediated S1P release inhibitor with an IC₅₀ of 94 nM ^[1].

HY-150254A

SLB1122168 formic	LPL Receptor	Inflammation/Immunology
SLB1122168 formic is a potent Spns2-mediated S1P release inhibitor with an IC₅₀ of 94 nM ^[1].

HY-158638

NBD-FTY720 phenoxy hydrochloride	Fluorescent Dye	Others
NBD-FTY720 phenoxy hydrochloride is a fluorescently-labeled analog of FTY720. FTY720 (HY-12005) is a potent sphingosine 1-phosphate (S1P) receptors modulator ^[1].

HY-12288

Ozanimod 3 Publications Verification RPC-1063	LPL Receptor	Neurological Disease Inflammation/Immunology
Ozanimod (RPC-1063), a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P₁ and hS1P₅ receptor with EC₅₀s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS) ^[1].

HY-12288A

Ozanimod hydrochloride 3 Publications Verification RPC-1063 hydrochloride	LPL Receptor	Neurological Disease Inflammation/Immunology
Ozanimod (RPC-1063) hydrochloride, a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod hydrochloride has modulate effect for hS1P₁ and hS1P₅ receptor with EC₅₀s of 1.03 nM and 8.6 nM, respectively. Ozanimod hydrochloride can be used for the research of relapsing multiple sclerosis (MS) ^[1].

HY-12288R

Ozanimod (Standard)	LPL Receptor	Neurological Disease Inflammation/Immunology
Ozanimod (Standard) is the analytical standard of Ozanimod. This product is intended for research and analytical applications. Ozanimod (RPC-1063), a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P₁ and hS1P₅ receptor with EC₅₀s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS) ^[1].

HY-103359

Ceranib1	Ceramidase	Cancer
Ceranib1 is a ceramidase inhibitor. Ceranib1 inhibits ceramidase activity toward an exogenous ceramide analog, induces the accumulation of multiple ceramide species, decreases levels of sphingosine and S1P. Ceranib1 inhibits the proliferation of ovarian cancer cells ^[1].

HY-162655

SLF80821178	LPL Receptor	Neurological Disease
SLF80821178 is a potent and orally active inhibitor of Sphingosine-1-Phosphate Transporter (Spns2). SLF80821178 inhibits S1P release with an IC₅₀ of 51 nM in HeLa cells and a T_1/2 of 2.4 h in mouse ^[1].

HY-12355S

Siponimod-d11 BAF-312-d₁₁	LPL Receptor Isotope-Labeled Compounds	Neurological Disease Inflammation/Immunology
Siponimod-d11 is deuterium labeled Siponimod (HY-12355). Siponimod is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for *S1P₁* and *S1P₅* over *S1P₂, S1P₃, and S1P₄, with EC₅₀s* of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research ^[1] .

HY-12355

Siponimod 5+ Cited Publications BAF-312	LPL Receptor	Neurological Disease Inflammation/Immunology
Siponimod (BAF-312) is an orally active and selective *sphingosine-1-phosphate* (S1P) receptor modulator. Siponimod is selective for *S1P₁* and *S1P₅* over S1P₂, S1P₃, and S1P₄, with EC₅₀s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research ^[1] ^- .

HY-162655A

SLF80821178 hydrochloride	LPL Receptor	Inflammation/Immunology
SLF80821178 hydrochloride is an orally active inhibitor for sphingosine-1-phosphate transporter (Spns2), that inhibits the sphingosine-1-phosphate (S1P) release in HeLa with an IC₅₀ of 51 nM. SLF80821178 hydrochloride reduces the circulating lymphocyte without affecting plasma S1P levels in mice ^[1].

HY-12355A

Siponimod hemifumarate BAF-312 hemifumarate	LPL Receptor	Neurological Disease Inflammation/Immunology
Siponimod (BAF-312) hemifumarate is a potent and selective **sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC₅₀**s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively). Siponimod hemifumarate can be used for multiple sclerosis (MS) research ^[1] .

HY-13447A

PF429242 dihydrochloride 5+ Cited Publications	Fatty Acid Synthase (FASN) Virus Protease	Infection Metabolic Disease
PF429242 dihydrochloride is a reversible and competitive SREBP site 1 protease (S1P) inhibitor with an IC₅₀ of 175 nM ^[1].

HY-13447

PF-429242	Fatty Acid Synthase (FASN) Virus Protease	Infection Metabolic Disease
PF429242 is a reversible and competitive SREBP site 1 protease (S1P) inhibitor with an IC₅₀ of 175 nM ^[1].

HY-116147

Ceranib-2	LPL Receptor Apoptosis	Cancer
Ceranib-2 is a potent and nonlipid ceramidase inhibitor that inhibits cellular ceramidase activity with an IC₅₀ of 28 μM in SKOV3 cells. Ceranib-2 induces the accumulation of multiple ceramide species, decreases levels of sphingosine and **sphingosine-1-phosphate (S1P), and induces cell apoptosis**. Anticancer activity ^[1] .

HY-12355R

Siponimod (Standard)	LPL Receptor	Neurological Disease Inflammation/Immunology
Siponimod (Standard) is the analytical standard of Siponimod. This product is intended for research and analytical applications. Siponimod (BAF-312) is an orally active and selective *sphingosine-1-phosphate* (S1P) receptor modulator. Siponimod is selective for *S1P₁* and *S1P₅* over S1P₂, S1P₃, and S1P₄, with EC₅₀s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research ^[1] ^- .

HY-148801

Tamuzimod	LPL Receptor	Inflammation/Immunology
Tamuzimod is a potent immunomodulator. Tamuzimod has S1P Receptor modulatory activity with an EC₅₀ of <1 μM ^[1] .

HY-139094

A6770	LPL Receptor	Metabolic Disease
A6770 is an orally active, potent sphingosine 1-phosphate (S1P) lyase (S1PL) inhibitor. A6770 is phosphorylated and the phosphorylated form directly inhibits S1P lyased.A6770, a potential key metabolite of THI, induces a [ ³H]dhS1P increase ^[1] .

HY-12005R

Fingolimod (hydrochloride) (Standard) FTY720 (Standard)	LPL Receptor PAK	Inflammation/Immunology Cancer
Fingolimod (hydrochloride) (Standard) is the analytical standard of Fingolimod (hydrochloride). This product is intended for research and analytical applications. Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a *pak1* activator ^[1] .

HY-N2553

4-Deoxypyridoxine 5'-phosphate	LPL Receptor	Metabolic Disease
4-Deoxypyridoxine 5'-phosphate is a Pyridoxal 5'-phosphate analogue and a sphingosine 1-phosphate (S1P) inhibitor. 4-Deoxypyridoxine 5'-phosphate inhibits ornithine decarboxylase activity with a K_i of 60 μM. 4-Deoxypyridoxine 5'-phosphate is a competitive inhibitor of the activation of glutamate apodecarboxylase by Pyridoxal 5'-phosphate (K_i of 0.27 μM) and strongly inhibits glutamate-dependent labeling of glutamate decarboxylase ^[1] .

HY-14113

2-Acetyl-4-tetrahydroxybutyl imidazole	LPL Receptor	Inflammation/Immunology
2-Acetyl-5-tetrahydroxybutyl imidazole is a potent sphingosine-1-phosphate (S1P) lyase inhibitor in vivo.

HY-15382A

(S)-FTY720-phosphonate	LPL Receptor	Inflammation/Immunology
FTY720 (S)-Phosphate is an agonist of S1P receptor 1 (S1PR1), used in the research of acute inflammatory diseases such as acute lung injury.

HY-15382

FTY720 (S)-Phosphate 2 Publications Verification (S)-FTY720P; (S)-FTY720 phosphate	LPL Receptor	Inflammation/Immunology
FTY720 (S)-Phosphate is an agonist of S1P receptor 1 (S1PR1), used in the research of acute inflammatory diseases such as acute lung injury.

HY-12895

SKI V 1 Publications Verification	SphK PI3K Apoptosis	Cancer
SKI V is a noncompetitive and potent non-lipid sphingosine kinase (SPHK; SK) inhibitor with an IC₅₀ of 2 μM for GST-hSK. SKI V potently inhibits PI3K with an IC₅₀ of 6 μM for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V induces apoptosis and has antitumor activity ^[1] .

HY-119401

CAY10444 1 Publications Verification BML-241	LPL Receptor	Cancer
CAY10444 (BML-241) is a **sphingosine-1-phosphate 3 (S1P3)** antagonist. CAY10444 inhibits by 37% S1P-induced increases in Ca²⁺ in HeLa cells expressing S1P3 receptors ^[1].

HY-149004B

SLF1081851 hydrochloride	LPL Receptor	Inflammation/Immunology
SLF1081851 (hydrochloride) is a Spns2 inhibitor, inhibits *S1P* release (IC₅₀=1.93 μM). SLF1081851 (hydrochloride) plays a key role in the development and immune system ^[1].

HY-14370

LX2931	LPL Receptor	Others Inflammation/Immunology
LX2931 is an inhibitor of Sphingosine 1-Phosphate Lyase (S1PL). LX2931 works by increasing levels of *S1P* inside and outside the cell. The decrease in *S1PL* activity leads to a significant increase in *S1P* content in tissues, especially in lymphoid tissues which may lead to a restricted exodus of lymphocytes from secondary immune tissues, resulting in lymphocytopenic and immunosuppressive effects in the peripheral circulation. LX2931 can be used in research for the treatment of autoimmune diseases, especially rheumatoid arthritis ^[1].

HY-149004

SLF1081851 3 Publications Verification	LPL Receptor	Inflammation/Immunology
SLF1081851 is a Spns2 inhibitor, inhibits *S1P* release (IC₅₀=1.93 μM). SLF1081851 plays a key role in development and immune system ^[1] .

HY-11063

Fingolimod Maximum Cited Publications 47 Publications Verification FTY720 free base	LPL Receptor PAK	Inflammation/Immunology Cancer
Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC₅₀ of 0.033 nM in K562 and NK cells. Fingolimod also is a *pak1* activator, a immunosuppressant ^[1].

HY-120268

SLM6031434	SphK	Inflammation/Immunology Cancer
SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with K_is of 0.4 μM, 0.5 μM, >20 μM, 22 μM for mSphK2, rSphK2, mSphK1 and rSphK1, respectively. SLM6031434 decrease Sphingosine 1-phosphate (S1P) levels in U937 monocytic leukemia cells. SLM6031434 has the potential for renal fibrosis research ^[1].

HY-15425

PF-543 5+ Cited Publications Sphingosine Kinase 1 Inhibitor II	SphK LPL Receptor Apoptosis Autophagy	Cardiovascular Disease Inflammation/Immunology Cancer
PF-543 (Sphingosine Kinase 1 Inhibitor II) is a potent, selective, reversible and sphingosine-competitive *SPHK1* inhibitor with an IC₅₀ of 2 nM and a K_i of 3.6 nM. PF-543 is >100-fold selectivity for *SPHK1* over SPHK2. PF-543 is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC₅₀ of 26.7 nM. PF-543 induces apoptosis, necrosis, and autophagy ^[1] .

Cat. No.	Product Name	Type

HY-W127793

EDTA-p-Bromoacetamido benzyl (S)-1-(p-Bromoacetamidobenzyl)ethylenediaminetetraacetic acid	Chelators
EDTA-p-Bromoacetamido benzyl ((S)-1-(p-Bromoacetamidobenzyl)ethylenediaminetetraacetic acid) is a compound of EDTA and phenylbromoacetamide that can be coupled to antibodies ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P99318

Sonepcizumab LT 1009; Anti-Human S1P Recombinant Antibody	LPL Receptor	Cancer
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-108496

Sphingosine-1-phosphate 5+ Cited Publications S1P	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite LPL Receptor
Sphingosine-1-phosphate (S1P) is an agonist of S1P_1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca ²⁺ as an extracellular ligand for G protein-coupled receptors ^[1]. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids . Sphingosine-1-phosphate stimulates the DNA synthesis, cell proliferation and migration .

Cat. No.	Product Name	Chemical Structure

HY-108496S

Sphingosine-1-phosphate-d7

Sphingosine-1-phosphate-d₇ is the deuterium labeled Sphingosine-1-phosphate. Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca2+ as an extracellular ligand for G protein-coupled receptors[1]. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids[2].

HY-11063S1

Fingolimod-d4 hydrochloride
Fingolimod-d₄ (hydrochloride) is the deuterium labeled Fingolimod hydrochloride. Fingolimod hydrochloride (FTY720) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride (FTY720) also is a pak1 activator, a immunosuppressant[1].

HY-11063S

Fingolimod-d4
Fingolimod-d₄ is the deuterium labeled Fingolimod. Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant[1].

HY-W011338S

Benzyl butyl phthalate-d4

Benzyl butyl phthalate-d₄ is the deuterium labeled Benzyl butyl phthalate[1]. Benzyl butyl phthalate, a member of phthalic acid esters (PAEs), can trigger the migration and invasion of hemangioma (HA) cells via upregulation of Zeb1. Benzyl butyl phthalate activates aryl hydrocarbon receptor (AhR) in breast cancer cells to stimulate SPHK1/S1P/S1PR3 signaling and enhances formation of metastasis-initiating breast cancer stem cells (BCSCs)[2][3][4].

HY-10569S1

Ponesimod-d7

Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation ^[1] .

HY-12355S

Siponimod-d11

Siponimod-d11 is deuterium labeled Siponimod (HY-12355). Siponimod is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P₁ and S1P₅ over S1P₂, S1P₃, and S1P₄, with EC₅₀s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research ^[1] .

HY-10569S

Ponesimod-d4

Ponesimod-d₄ (ACT-128800-d₄) is the deuterium labeled Ponesimod (HY-10569) ^[1]. Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82614

	EDG3 Antibody (YA2359) S1PR3; EDG3; Sphingosine 1-phosphate receptor 3; S1P receptor 3; S1P3; Endothelial differentiation G-protein coupled receptor 3; Sphingosine 1-phosphate receptor Edg-3; S1P receptor Edg-3	WB	Human, Mouse, Rat
	EDG3 Antibody (YA2359) is a non-conjugated IgG antibody, targeting EDG3, with a predicted molecular weight of 42 kDa (observed band size: 42 kDa). EDG3 Antibody (YA2359) can be used for WB experiment in human, mouse, rat background.

HY-P80967

	S1PR4 Antibody EDG6; LPC1; S1P4; SLP4	WB, IHC-P	Rat
	S1PR4 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 42 kDa, targeting to S1PR4. It can be used for WB, IHC-P assays with tag free, in the background of Rat.

HY-P81494

	EDG1 Antibody (YA1239) S1PR1; EDG1; S1P1; ECGF1; EDG-1; CHEDG1; D1S3362	IHC-P	Human
	EDG1 Antibody (YA1239) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1239), targeting EDG1. EDG1 Antibody (YA1239) can be used for IHC-P experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks